Association of the British Pharmaceutical Industry
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
Number of women in England receiving HRT on the NHS more than doubles
A record two million women were prescribed hormone replacement therapy in 2025/26 compared to 0.8 million in 2020/21
New benchmark reveals significant digital maturity gap across UK POM companies’ product-information estates
A new benchmark maps 100 UK prescription medicine companies across five maturity bands and finds a market at very different stages of digital development
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands
Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing...
Why pharma website projects stall long before compliance becomes the problem
Pharma teams often blame compliance when digital projects slow down. In reality, the bigger issue is usually weaker ownership, unclear review models and content structures that were never designed for...
Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo
This is the first approved treatment option in the UK for patients with non-segmental vitiligo
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
UK and US agree on landmark pharma pricing tariff deal
US tariffs on UK-produced pharmaceuticals will remain at zero for three years
ViiV Healthcare receives NICE recommendation for HIV prevention therapy
The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales
Pfizer’s Lorviqua recommended by NICE for lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide
New National Commission launched to strengthen AI regulation
The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance